Studies report mixed-and sometimes mutually incompatible-data about whether the drug increases the risk of colorectal cancer.
Patients who received ipilimumab as adjuvant therapy had improved recurrent-free survival, but also high rates of toxicity.
Researchers interpreting results from studies using adaptive randomization must be aware of assumptions made during study.
Some health care insurers have stopped covering this FDA-approved genetic test, instead limiting coverage only for cheaper, lower-quality genetic tests.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
The role of payments to hospitals and physicians is not well understood, despite attempts to quantify them.
From the Advisory Board
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Insurance Plans Dropping Coverage of FDA-approved BRCA Diagnostic Test
- Genomic Information and the Future of Health Care
- Psychological Stress and Chronic Illness Among Survivors of Cancer
- Model Suggests Best Option in CML Is Sequential Combination of Dasatinib and Nilotinib
- Denosumab Non-inferior to Zoledronic Acid for Delaying Time to Skeletal-related Event
- Adding Seribantumab to Paclitaxel Fails to Improve PFS in Advanced Ovarian Cancer
- Treatment Facility Volume Linked to Mortality in Multiple Myeloma
- Multi-agent Chemotherapy Not Recommended To Replace Chemoradiotherapy in Rectal Cancer
- Mitoxantrone and Colorectal Cancer: Is There an Increased Risk?
- FDA Grants Priority Review to Nivolumab for Advanced Bladder Cancer